BeiGene

Duo Oncology specializes in developing nanoparticle technology designed to penetrate established tumors efficiently. Collaborating with renowned university scientists and medical oncologists, the company aims to accelerate product development through strategic partnerships with established research organizations.

Strand Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in genetically programming mRNA to deliver innovative therapies aimed at enhancing patient outcomes. Founded in 2017, the company develops mRNA programming technology that allows for precise control over the location, timing, and intensity of therapeutic protein expression within the body. By employing mRNA-encoded logic circuits, Strand Therapeutics can achieve cell-type specific expression by detecting unique miRNA signatures and modulating protein dosage in response to externally administered small molecules. The company focuses on creating gene therapies powered by synthetic biology, including immunotherapies designed to enable cells to produce target cancer-killing proteins, thereby strengthening the body's immune response against cancer.

Boston Immune Technologies & Therapeutics, Inc. is a biopharmaceutical company focused on developing immune-based therapies for cancer and infectious diseases. Incorporated in 2011 and located in Winchester, Massachusetts, the company has created a platform that targets the tumor necrosis factor receptor 2 (TNFR2) oncogene and the specific population of TNFR2 regulatory T cells within the tumor microenvironment. This innovative approach aims to enhance immunotherapy strategies, particularly for chronic infectious diseases, by leveraging the body's immune system to combat various health challenges.

Singlomics is a biotechnology company that leverages single-cell sequencing technology to develop innovative antibody drugs aimed at treating infectious diseases and cancers. The company focuses on the discovery and development of neutralizing antibodies, including DXP593 and DXP604, which serve as potential therapeutic solutions against COVID-19. By utilizing advanced sequencing techniques, Singlomics aims to enhance the efficacy of antibody treatments and address significant health challenges in infectious diseases and oncology.

Leap Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics. Its primary focus is to advance translational-stage molecules in cell signaling and immuno-oncology areas.